Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer

Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III... Letters 1. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited cal trials—from overall survival to progression-free survival, du- 2,3 metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA rability of response, and objective response rate. We believe Oncol. 2018;4(1):e173501. doi:10.1001/jamaoncol.2017.3501 that this shift in outcomes in clinical trials is about accepting 2. Sacher AG, Le LW, Leighl NB. Shifting patterns in the interpretation of phase that survival improvements in advanced-stage lung cancer are III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is multifactorial and more difficult to achieve, and ultimately dis- dropping. J Clin Oncol. 2014;32(14):1407-1411. doi:10.1200/JCO.2013.52.7804 tancing us mentally from the concept of cure and shifting to a 3. Johnson DH. Setting the bar for therapeutic trials in non-small-cell lung cancer: how low can we go? J Clin Oncol. 2014;32(14):1389-1391. different perspective with respect to metastatic disease. doi:10.1200/JCO.2014.55.1929 We do not cure diabetes, heart failure, or chronic obstruc- tive pulmonary disease. All of the medical and surgical inter- ventions that we offer patients with these illnesses are imple- Beyond Primary Tumor Location and RAS/BRAF mented in the hope of improving patients’ quality of life and Mutational Status as Prognostic http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer

Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer

Abstract

Letters 1. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited cal trials—from overall survival to progression-free survival, du- 2,3 metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA rability of response, and objective response rate. We believe Oncol. 2018;4(1):e173501. doi:10.1001/jamaoncol.2017.3501 that this shift in outcomes in clinical trials is about accepting 2. Sacher AG, Le LW, Leighl NB. Shifting patterns in the...
Loading next page...
 
/lp/american-medical-association/beyond-primary-tumor-location-and-ras-braf-mutational-status-as-tOqVbaYIPD
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2018.1692
Publisher site
See Article on Publisher Site

Abstract

Letters 1. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited cal trials—from overall survival to progression-free survival, du- 2,3 metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA rability of response, and objective response rate. We believe Oncol. 2018;4(1):e173501. doi:10.1001/jamaoncol.2017.3501 that this shift in outcomes in clinical trials is about accepting 2. Sacher AG, Le LW, Leighl NB. Shifting patterns in the interpretation of phase that survival improvements in advanced-stage lung cancer are III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is multifactorial and more difficult to achieve, and ultimately dis- dropping. J Clin Oncol. 2014;32(14):1407-1411. doi:10.1200/JCO.2013.52.7804 tancing us mentally from the concept of cure and shifting to a 3. Johnson DH. Setting the bar for therapeutic trials in non-small-cell lung cancer: how low can we go? J Clin Oncol. 2014;32(14):1389-1391. different perspective with respect to metastatic disease. doi:10.1200/JCO.2014.55.1929 We do not cure diabetes, heart failure, or chronic obstruc- tive pulmonary disease. All of the medical and surgical inter- ventions that we offer patients with these illnesses are imple- Beyond Primary Tumor Location and RAS/BRAF mented in the hope of improving patients’ quality of life and Mutational Status as Prognostic

Journal

JAMA OncologyAmerican Medical Association

Published: Sep 12, 2018

References